Boehringer Ingelheim, a company involved in animal health, announce on Thursday the upcoming release of its Purevax(R) vaccine range for cats in 0.5ml presentation.

The company said that thanks to its small volume, this new presentation of Purevax(R) makes cat vaccination convenient, allowing for a gentler immunisation experience for feline patients.

The Purevax(R) range protects cats from contracting the most important infectious feline diseases: feline herpesvirus (FHV) and feline calicivirus (FCV), feline panleukopenia virus (FPV), chlamydia felis, feline leukaemia virus (FeLV) as well as rabies. Purevax(R) is claimed to be the only fully adjuvant-free feline vaccine range, combining optimal safety with proven efficacy. The Purevax(R) range also allows for flexibility by using the core components alone or in combination with non-core components, depending on the cat's individual need.

Dr Sandrine Lacherade, global marketing director Pet Vaccines at Boehringer Ingelheim, commented, 'Purevax(R) 0.5ml offers the same broad and flexible product range as Purevax(R) 1.0ml, with tailor-made solutions to suit every cat's lifestyle. The new cat-friendly injection volume of 0.5ml is a key benefit we are very excited about. Veterinarians can count on Purevax(R) 0.5ml to have the same efficacy as the Purevax(R) 1.0ml range.'